GPScreen™은 세계 최초로 상용화된 혁신적인 약물 작용점 탐색 서비스입니다. 한국 생명공학연구원과 바이오니아 및 영국 왕립 암 연구소의 공동 연구로 개발되어Nat. Biotech (Kim DU et al, 2010)에 보고된 4800여 개의 변이체로 구성된 분열 효모인
S. pombe genome-wide heterozygous deletion mutant library 를 이용하여 작용점이 규명되지 않은 약물들의 작용점을 빠른 시간 안에 효과적으로 분석해 드립니다.
또한,
GPScreen™을 통해 밝혀진 약물 작용점은
- in vitro siRNA Susceptibility Test 서비스
- in vivo SAMiRNA Validation Test 서비스
과 같은 추가적인 서비스를 통해 인간 세포 수준에서 최종적으로 작용점의 유효성을 분석해 드립니다.
GPScreen™ 서비스는 작용점이 규명되지 않은 약효 물질들의 정확한 작용점 규명을 통하여 drug repositioning , 천연물의 작용 기전 및 약물 부작용의 원인 규명과 같은 신약 개발을 위한 핵심적인 issue들을 해결함으로써, 궁극적으로 고객의 신약 개발의 성공률을 크게 개선시켜 드릴 것입니다.
Features & Benefits of GPScreen™ Services
- World's unique & innovative technology
- Identify any classes of targets in genome through genome-wide screening
- Live cell-based screening
- High throughput screening
- Rapid; average 20 days for genome-wide screening
- Accurate, precise & cost-effective
- Drug target validation services available in human cells (optional !)
- Applicable to drug repositioning, natural drug target discovery, toxicity profiling
Ⅰ. Introduction
Precise Drug Target Identification is a first step for improving efficacy,
tracing and avoiding side-effects as well as understanding the mode-of-actions of drug candidates.
However, until now, effective systematic approaches for the precise drug target identification at genome levels
have not been commercially available. Using S. pombe genome-wide heterozygous deletion mutant library,
Bioneer has developed a high-throughput genome-wide drug target screening service system (GPScreen™) and
made it commercially available for your drug discovery needs. GPScreen™ screening service covers a broad spectrum
of drug candidates in whole disease areas from cancers & metabolic diseases to neglected & rare diseases and, therefore,
will provide the total solutions for an efficient drug discovery through providing clear-cut answers to problems such
as drug-target(s) and toxicity as well as mode-of-actions of drug candidates.
"Bioneer's GPScreen™ using S. pombe genome-wide heterozygous deletion mutant library has enabled genome-wide screening for drug target identification"
GPScreen™ is based on Bioneer's unique S. pombe genome-wide deletion mutant library, which was developed by Bioneer and the Korea Research Institute of Bioscience & Biotechnology
(KRIBB) in collaboration with Dr. Paul Nurse of Cancer Research Center UK (Nat. Biotech, 28, 617–623 (2010)).
It can be used for genetic and chemical screening such as drug target identification,
gene expression profiling and synthetic lethal profiling.
This mutant library comprised of a total of 4,840 heterozygous diploid deletion mutants representing 98.5%
genome coverage and one copy of a specific gene in each mutant was deleted by homologous recombination. GPScreen™ exclusively offers S. pombe deletion mutant library as a powerful tool for large-scale genetic functional
analysis, identification and verification research of drug targets and for integrated systems research of cell function.
Ⅱ. Principle of GPScreen™
"Drug-induced Haploinsufficiency (DIH)" is a situation in which a strain with a heterozygous gene deletion (producing target proteins to about half of normal levels),
result in cells sensitive to a specific drug. DIH occurs when a drug or drug candidate acts on a mutant strain in which the level of target gene protein is lowered from normal to half level,
and is considered to be a valuable tool for drug target identification. Previously, a number of reports have provided identifications of drug targets using DIH in budding yeast S. cerevisiae (Baetz K et al., 2004; Lum et al., 2004). However, fission yeast S. pombe is considered a better model of mammalian cells since its cell cycle regulation is closer to that
of mammalian cells than that of S. cerevisiae
 |
"GPScreen™ utilizes DIH in the fission yeast S. pombe genome-wide heterozygous deletion mutant library to identify the drug target(s). |
References
• Baetz K et al. Yeast genome-wide drug-induced haploinsufficiency screen to determine drug mode of action. PNAS. 2004
[More information]
• Lum PY et al. Discovering modes of action for therapeutic compounds using a genome-wide screen of yeast heterozygotes. Cell. 2004
[More information]
Ⅲ. Performance of GPScreen™
GPScreen™ is a best-in class genome-wide drug target identification system that is exclusively offered by Bioneer Inc. It allows for the clear-cut identification of molecular targets of drugs/ drug candidates (A representative is below). 
Figure 1. Drug Target Identification using GPScreen™.
In the presence of cytochalasin A (Fig. 1A), a heterozygous deletion mutant of act1 shows decreased growth as a result of a decrease in "functional" Act1 protein. act1 was the only gene in the genome-wide screen to show this effect, demonstrating that act1 is a target of cytochalasin A (Fig. 1B).
IV. Applications of GPScreen™
- Toxicity profiling and Drug Prioritization
- Drug Repositioning and Enhancement
- Natural Drug Target Discovery
- Chemogenomic profiling
Toxicity profiling using GPScreen™ at early stage of drug development would accommodate 'Drug Prioritization' among drug candidates very efficiently, thereby reducing time and money dramatically in the later stage of drug discovery.
V. Flow chart of GPScreen™ Service
